NervGen Pharma (NGEN) announced that the company has elected to voluntarily delist its common shares from TSX Venture Exchange, effective at the close of markets on March 16.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
- Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
- NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
- NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
- NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase